295 related articles for article (PubMed ID: 29345737)
1. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
2. [Active immunotherapy of urologic malignancies and tumor-mediated immunosuppression].
Kübler H; Gschwend JE
Urologe A; 2008 Sep; 47(9):1122-7. PubMed ID: 18704362
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
4. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
5. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.
Bergerot CD; Bergerot PG; Philip EJ; Hsu JA; Dizman N; Vaishampayan U; Dorff T; Pal SK
J Immunother Cancer; 2019 Mar; 7(1):71. PubMed ID: 30867071
[TBL] [Abstract][Full Text] [Related]
6. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
7. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in immunotherapy for urological cancer.
Obara W; Kato R; Kato Y; Kanehira M; Takata R
Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Bellmunt J; Ribas A
Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
[No Abstract] [Full Text] [Related]
10. [Immunooncology in Urologic Cancers: Current Status].
Grimm MO
Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
[TBL] [Abstract][Full Text] [Related]
11. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Clark PE
Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
[No Abstract] [Full Text] [Related]
13. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
15. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
16. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for melanoma and renal cell carcinoma.
Kaufman HL
Semin Oncol; 2012 Jun; 39(3):263-75. PubMed ID: 22595049
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Noguchi M; Koga N; Moriya F; Suekane S; Yutani S; Yamada A; Shichijo S; Kakuma T; Itoh K
Cancer Sci; 2018 Sep; 109(9):2660-2669. PubMed ID: 29938870
[TBL] [Abstract][Full Text] [Related]
19. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
[TBL] [Abstract][Full Text] [Related]
20. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
